A European court will decide on July 13 whether San Diego life sciences company Illumina’s $8 billion cash-and-stock takeover of Grail should be scrutinized by EU antitrust regulators, people familiar with the matter said on Wednesday.
A European court will decide on July 13 whether San Diego life sciences company Illumina’s $8 billion cash-and-stock takeover of Grail should be scrutinized by EU antitrust regulators, people familiar with the matter said on Wednesday.
This website, like most media sites, uses small files called cookies to anonymously customize the advertising that you see. Learn more about how we use cookies in our cookie policy.
